Effect of Rivaroxaban on hemostasis in patients with alcoholic cirrhosis of the liver in combination with obesity-Reference-Cited by-同舟云学术

Effect of Rivaroxaban on hemostasis in patients with alcoholic cirrhosis of the liver in combination with obesity

Published:2020-06-30 Issue:2 Volume:87 Page:26-35
ISSN:2414-4495
Container-title:Medicine Today and Tomorrow
language:uk
Short-container-title:MTT

Author:

Virstiuk N.G.¹^ORCID,Matkovska N.R.¹^ORCID,Vatseba B.R.¹^ORCID

Affiliation:

1. Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine

Abstract

The effect of rivaroxaban on hemostasis was investigated in patients with alcoholic liver cirrhosis (ALC) in combination with obesity and non-valvular atrial fibrillation (NVAF). The study included 48 obese patients with ALC of class A (according to the Child-Pugh score) with NVAF, who were not previously treated with direct oral anticoagulants. There are 43 men and 5 women aged 35 to 64 years, mean age is (54.2±4.8) years. Depending on the treatment, patients were divided into two groups: group I included 22 patients who received oral anticoagulant rivaroxaban at a dose of 10 mg/day for 12 months, group II included 26 patients who received basic therapy without rivaroxaban for 12 months. Assessment of the patients’ condition was performed before treatment, 12, 24 and 48 weeks after treatment onset. The severity of LC was assessed according to the Child-Pugh and the MELD scores. Stratification of the risk of bleeding was performed according to the HAS-BLED score. It is shown, that in obese patients with ALC of class A according to the Child-Pugh score in the presence of NVAF, the use of rivaroxaban in combination therapy for 48 weeks contributed to the positive dynamics of hemostasis: decreased factor VIII activity, von Willebrand factor activity, reduced plasminogen activator inhibitor-1, D-dimer levels (p<0.05) and an increase in the activity of protein C (p<0.05), which was accompanied by a moderate decrease in the Child-Pugh and the MELD scores, and this was not observed in the comparison group. The use of rivaroxaban in this cohort of patients for 48 weeks did not increase the risk of major bleeding according to the clinical course and the HAS-BLED score. It is proved that the use of rivaroxaban in the complex treatment of patients with ALC of class A (according to the Child-Pugh score) in combination with obesity and NVAF, contributes to the positive dynamics of hemostasis with a reduced risk of hypercoagulation. Such therapy does not increase the risk of major bleeding at the stage of compensation of ALC in combination with obesity and NVAF.

Publisher

Kharkiv National Medical University

Subject

General Earth and Planetary Sciences,General Environmental Science

Reference25 articles.

1. Nakaz MOZ Ukrainy vid 06.11.14 No.826. Pro zatverdzhennia ta vprovadzhennia medyko- tekhnolohichnykh dokumentiv zi standartyzatsii medychnoi dopomohy pry khronichnykh neinfektsiinykh hepatytakh: Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) medychnoi dopomohy "Alkoholnyi hepatyt"; Alkoholna khvoroba pechinky. Adaptovana klinichna nastanova, zasnovana na dokazakh [Order of the Ministry of Health of Ukraine dated November 6, 2014 No.826. On approval and implementation of medical and technological documents on standardization of medical care at chronic non-infectious hepatitis: Unified clinical protocol of primary, secondary (specialized) medical care "Alcoholic hepatitis"; Adapted clinical guidelines based on the evidence "Alcoholic liver disease"]. (2014). Retrieved from https://ukrgastro.com.ua/illnesses/ [in Ukrainian],

2. Nakaz MOZ Ukrainy No.597 vid 15.06.16. Pro zatverdzhennia ta vprovadzhennia medyko- tekhnolohichnykh dokumentiv zi standartyzatsii medychnoi dopomohy pry fibryliatsii peredserd: Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysoko- spetsializovanoi) medychnoi dopomohy "Fibryliatsiia peredserd" [Order of the Ministry of Health of Ukraine No.597 of 15.06.16. On approval and implementation of medical and technological documents for standardization of medical care for atrial fibrillation: Unified clinical protocol of primary, secondary (specialized) and tertiary (highly specialized) medical care "Atrial fibrillation"]. (2016). Retrieved from https://www.dec.gov.ua/wpcontent/uploads/2019/ll/2016_597_ykpmd_fibrpreds.pdf [in Ukrainian],

3. Nakaz MOZ Ukrainy vid 06.08.14 No.826. Pro zatverdzhennia ta vprovadzhennia medyko-tekhnolohichnykh dokumentiv zi standartyzatsii medychnoi dopomohy pry khronichnykh neinfektsiinykh hepatytakh: Unifikovanyi klinichnyi protokol "Alkoholnyi steatohepatyt" [Order ofthe Ministry of Health of Ukraine dated 06.08.14 No.826. On approval and implementation of medical and technological documents on standardization of medical care at chronic non-infectious hepatitis: Unified clinical protocol "Alcoholic steatohepatitis"]. (2014). Retrieved from https://ukrgastro.com.ua/illnesses/ [in Ukrainian],

4. Nakaz MOZ Ukrainy vid 06.11.14 No.826. Pro zatverdzhennia ta vprovadzhennia medyko- tekhnolohichnykh dokumentiv zi standartyzatsii medychnoi dopomohy pry khronichnykh neinfektsiinykh hepatytakh: Unifikovanyi klinichnyi protokol "Nealkoholnyi steatohepatyt" [Order of the Ministry of Health of Ukraine dated November 6, 2014 No.826. On approval and implementation of medical and technological documents on standardization of medical care at chronic non-infectious hepatitis: Unified clinical protocol "Non-alcoholic steatohepatitis"]. (2014). Retrieved from https://ukrgastro.com.ua/illnesses/ [in Ukrainian],

5. Ambrosino R, Tarantino L., Di Minno G., Paternoster M., Graziano V., Petitto M. et. al. (2017). The risk of venous thromboembolism in patients with cirrhosis. Thrombosis and Haemostasis, vol. 26, issue 1, pp. 139-148. DOI: 10.1160/TH16-06-0450, PMID: 27761574.